JAK Inhibitors in Alopecia Areata: Treatment Goals, Safety Data, and Long-Term Management

Dr. Ungar reads the Case 3 follow-up: the patient is a normal CYP2C9 metabolizer, with normal CBC, TSH, and ferritin, negative tuberculosis screening, and up-to-date immunizations. He then discusses treatment goals, which begin with a conversation about what the patient hopes for and what is realistic. Severe disease may take longer to regrow, and data show that ongoing therapy is important because only a small percentage maintain response off treatment. His overall goal is a patient who feels better and has minimal psychosocial burden, ideally with full regrowth.

For patients whose first therapy fails, counseling should start at initiation. He recommends cautious optimism, explaining that regrowth takes months and not everyone responds to the first drug. A failed first treatment does not predict failure of the next, and that hope helps patients stay positive.

On safety, he notes that class concerns come from tofacitinib, studied in a different disease. These are immunosuppressive medications, not zero-risk, but alopecia areata data across thousands of patients suggest risks are in line with background rates of myocardial infarction, deep vein thrombosis, and malignancy. Any increase appears minimal, so the risk-benefit balance is favorable. The differences among the three agents are small, access matters most, and this patient's normal CYP2C9 status makes deuruxolitinib a reasonable start.

For long-term management, stopping after regrowth carries a high likelihood of lost response. Dr. Ungar checks labs about every three months initially and spaces them out later. He also schedules regular follow-up and encourages patients to call between visits about flares, since fear of relapse persists.

Up next, in "Patient Perspective on Alopecia Areata: Sudden Hair Loss and Delayed Diagnosis," a patient with alopecia areata universalis recounts how her hair loss began and why diagnosis took months.